ESTRO 2025 - Abstract Book

S54

Invited Speaker

ESTRO 2025

4733

Speaker Abstracts Radionuclide therapy and immune effects Sandra Heskamp Medical Imaging, Nuclear Medicine, Radboudumc, Nijmegen, Netherlands

Abstract:

The immune-sensitizing effects of radiation have been studied in depth for external beam radiotherapy. In the field of targeted radionuclide therapy (TRT), these effects are just starting to be explored in a more systemic manner. This presentation will provide an overview of TRT-induced immunological effects observed in preclinical and clinical studies, specific challenges related to TRTs radiation properties in the context of the immune response, and current status of TRT and immunotherapy combination treatment approaches.

4734

Speaker Abstracts Development and radiobiological evaluation of novel radiopharmaceuticals: From lab to company Ann-Christin Eder Department of Nuclear Medicine, University Medical Center Freiburg, Freiburg, Germany

Abstract:

The rapid development of targeted radiopharmaceuticals represents one of the most promising frontiers in nuclear medicine, offering new opportunities for both diagnostic imaging and therapeutic applications. This presentation will provide a focused overview of the key steps in translating radiopharmaceutical concepts from laboratory discoveries to commercial products, with an emphasis on the theranostic paradigm. Starting with the radiopharmaceutical development pipeline, critical decision points that determine which candidate molecules advance towards clinical translation will be highlighted. The presentation will examine how the selection of appropriate radionuclides and targeting vectors forms the basis of successful radiopharmaceutical design, particularly for theranostic applications where diagnostic and therapeutic agents share the same targeting mechanism. To illustrate these principles in practice, selected success stories in theranostic radiopharmaceutical development will show how academic discoveries have been effectively translated into clinical tools. These examples will highlight not only the scientific advances, but also the strategic partnerships and commercialization pathways that facilitated their journey to patient care. In this context, intellectual property considerations will be addressed as critical elements of successful development.

The presentation will conclude with an exploration of future opportunities in this rapidly evolving field, highlighting emerging technologies and unmet clinical needs that represent promising avenues for continued innovation.

By distilling the complex journey of radiopharmaceutical development into its essential components, this presentation aims to provide valuable insights for advancing novel radiopharmaceuticals from promising concepts to clinical reality.